RVL Pharmaceuticals is dedicated to advancing eyecare and medical aesthetics through innovative pharmaceutical solutions. The company focuses on developing products that address specific patient needs, particularly in the fields of neurology and ophthalmology. Their approach encompasses the entire process from concept to commercialization, ensuring that their offerings are not only effective but also aligned with the latest advancements in medical science. This commitment to patient outcomes is further supported by their Grants and Contributions Office, which collaborates with the healthcare community to fund educational initiatives and investigator-initiated studies that align with the company's strategic focus.

In addition to their product development efforts, RVL Pharmaceuticals emphasizes the importance of research and education in enhancing patient care. They actively seek partnerships with healthcare professionals and organizations to support projects that can lead to improved treatment options and outcomes. By prioritizing educational grants and research initiatives, RVL aims to foster innovation and knowledge sharing within the medical community, ultimately benefiting patients who rely on their specialized eyecare and medical aesthetic products.

United States

RVL Pharmaceuticals (previously named Osmotica Pharmaceutical; Nasdaq: OSMT) is a fully-integrated pharmaceutical company with demonstrated expertise in developing commercially successful products. As one of the world's leading osmotic drug delivery companies, we leverage our significant resources in R&D and proprietary drug delivery technology to address the growing need of the global patient population.

We have the resources and experience to successfully commercialize our products through our subsidiaries, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC.



Eye Diseases

RVL Pharmaceuticals 

Blepharoptosis

Eye disease

Oxymetazoline is an alpha adrenoceptor agonist targeting a subset of adrenoreceptors in Mueller’s muscle of the eyelid.
Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, which when administered to the eye, is believed to selectively target Müller’s muscle and elevate the upper eyelid.&nbsp;Upneeq is the first and only FDA-approved pharmacologic treatment indicated for the treatment of acquired blepharoptosis (ptosis, or droopy eyelid).

Upneeq (RVL-1201)

Central nervous system illness

Multiple sclerosis

Selective gamma-amino-butyric acid type B receptor agonist, is designed to inhibit glutamate signalling, thereby inhibiting excessive metabotropic glutamate receptor (mGluR)-mediated protein synthesis.

RVL Pharmaceuticals

Company Details